The most altered genes in 414 thymic carcinomas evaluated using the Foundation Medicine assay were CDKN2A (39.9%), TP53 (30.2%), CDKN2B (24.6%), BAP1 (8.2%), TET2 (8.0%), KIT (8.0%), SETD2 (7.7%), NFKBIA (7.7%), ASXL1 (7.0%) and KMT2D (6.0%) [27]. The gene discussed is ASXL1; the disease is thymic carcinoma.